Our Pricing

Mounjaro Crofton: Evidence-Based Weight Loss Treatment

Published: 6 October 2026

Residents searching for Mounjaro Crofton now have access to this clinically proven weight loss injection through Cured Pharmacy, a fully UK-registered online service (GPhC 9012511). Tirzepatide, the active ingredient in Mounjaro, demonstrated average weight reductions of 15-20% in the SURMOUNT clinical trials, making it one of the most effective pharmacological interventions for obesity management [1]. All prescriptions require assessment by our UK clinical team, with discreet delivery available to Crofton and surrounding areas.

What Is Mounjaro Crofton and How Does It Work?

Mounjaro Crofton refers to the availability of tirzepatide weight loss injections for residents in the Crofton area through registered UK pharmacy services. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, originally licensed for type 2 diabetes management and subsequently approved by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities [2].

The dual-agonist mechanism distinguishes Mounjaro from single-pathway GLP-1 treatments. By activating both GIP and GLP-1 receptors, tirzepatide enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways [3]. Clinical data from the SURMOUNT-1 trial showed participants achieved average weight loss of 15.0% with the 5mg dose, 19.5% with 10mg, and 20.9% with the 15mg maintenance dose over 72 weeks [1]. These results represent some of the highest efficacy figures recorded for any obesity pharmacotherapy to date.

Mounjaro Crofton Pricing and Transparent Costs

Cured Pharmacy offers Mounjaro Crofton starting from £124.99 per prescription, with transparent upfront pricing displayed before any consultation begins. New patients can access £20 off their first order using code Weightlossnew, reducing the initial cost to £124.99. Unlike traditional high-street services, our online model eliminates overhead costs, allowing us to maintain competitive UK pricing whilst ensuring full regulatory compliance and clinical oversight.

The price includes the medication, UK prescriber assessment, and discreet home delivery to Crofton addresses. No hidden consultation fees or membership subscriptions are required. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical protocols to ensure patients receive genuine UK-licensed Mounjaro with appropriate medical supervision throughout their weight management journey.

Cost Comparison: Mounjaro Crofton vs Other Weight Loss Treatments

When evaluating Mounjaro Crofton against alternative weight loss medications, efficacy per pound spent becomes an important consideration. Whilst orlistat-based treatments start from £124.99, they typically produce 5-10% weight loss compared to Mounjaro's 15-20% average reduction [4]. Wegovy (semaglutide) injections start from £124.99 and demonstrated 14.9% average weight loss in the STEP-1 trial, positioning it between orlistat and tirzepatide in both cost and efficacy [5]. The comparison table below illustrates how Mounjaro Crofton compares across the weight loss treatment spectrum available through our service.

Accessing Mounjaro Crofton Through Online Consultation

Obtaining Mounjaro Crofton requires completion of a clinical assessment with a UK-registered prescriber, as tirzepatide is a prescription-only medicine under MHRA regulations. Our streamlined online consultation takes under 3 minutes and covers medical history, current medications, weight management goals, and contraindication screening. This ensures Mounjaro is clinically appropriate and safe for each individual patient.

Once submitted, a UK prescriber reviews the assessment within hours during business days. If approved, the prescription is dispensed by our GPhC-registered pharmacy and dispatched in 100% discreet packaging to your Crofton address. Patients receive ongoing support throughout treatment, with options to adjust dosing or discuss side effects with our clinical team. This model combines the convenience of online access with the safety standards of traditional pharmacy care.

Who Can Use Mounjaro Crofton?

Mounjaro Crofton is licensed for adults with a body mass index (BMI) of 30 kg/m² or greater, or BMI 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [2]. Patients must be willing to engage with lifestyle modifications including dietary changes and increased physical activity, as Mounjaro is most effective when combined with behavioural interventions. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and pregnancy or breastfeeding.

Mounjaro Crofton Dosing Schedule and Administration

The Mounjaro Crofton treatment protocol follows a graduated dose escalation schedule designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes. All patients begin with a 2.5mg subcutaneous injection once weekly for four weeks. This starter dose allows the body to adapt to GIP/GLP-1 receptor activation before therapeutic doses are reached [3].

After the initial four weeks, the dose increases to 5mg weekly for another four-week period. Depending on individual response and tolerability, prescribers may further escalate to 7.5mg, 10mg, 12.5mg, or the maximum 15mg maintenance dose. Each dose increase occurs at four-week intervals, with clinical reassessment to evaluate weight loss progress, side effect burden, and patient adherence. The pre-filled KwikPen devices contain four weekly doses, administered via a simple subcutaneous injection into the abdomen, thigh, or upper arm.

Side Effects and Safety Considerations for Mounjaro Crofton

The most frequently reported side effects with Mounjaro Crofton involve the gastrointestinal system, consistent with the medication's mechanism of slowing gastric emptying. In clinical trials, nausea occurred in 12-29% of participants depending on dose, with diarrhoea affecting 13-21%, vomiting 6-11%, and constipation 6-11% [1]. These effects typically peak during dose escalation phases and diminish over subsequent weeks as tolerance develops.

More serious but rare adverse events include pancreatitis (reported in 0.2% of trial participants), gallbladder disease, acute kidney injury secondary to dehydration, and hypoglycaemia when used concurrently with insulin or sulfonylureas [2]. Patients should be counselled to report severe abdominal pain, persistent vomiting, or signs of dehydration immediately. Our clinical team at Cured Pharmacy monitors all Mounjaro Crofton patients for adverse events and provides guidance on managing common side effects through dietary adjustments and symptomatic relief measures.

Managing Mounjaro Crofton Side Effects

Practical strategies can significantly reduce the gastrointestinal burden associated with Mounjaro Crofton. Eating smaller, more frequent meals rather than large portions helps accommodate delayed gastric emptying. Avoiding high-fat foods, which exacerbate nausea, and staying well-hydrated throughout the day prevents dehydration-related complications. If nausea persists, taking the injection in the evening rather than morning may improve daytime tolerance. Our pharmacist team provides personalised advice on side effect management as part of the ongoing support included with every Mounjaro Crofton prescription.

Long-Term Weight Maintenance with Mounjaro Crofton

Clinical trial data demonstrates that weight loss achieved with Mounjaro Crofton is maintained as long as treatment continues, but significant weight regain occurs upon discontinuation. The SURMOUNT-4 trial specifically examined this phenomenon: participants who achieved weight loss on tirzepatide and then switched to placebo regained an average of 14% body weight over the subsequent 52 weeks, whilst those continuing tirzepatide lost an additional 5.5% [6]. This highlights that obesity is a chronic disease requiring ongoing pharmacological management in many patients.

For Crofton residents considering Mounjaro, realistic expectations about treatment duration are essential. Most patients require continuous therapy to maintain weight loss, similar to how hypertension or diabetes medications are used long-term. Our clinical team works with each patient to develop sustainable treatment plans that balance efficacy, cost considerations, and individual weight management goals. Combining Mounjaro Crofton with permanent lifestyle modifications—dietary pattern changes, regular physical activity, and behavioural strategies—optimises the likelihood of maintaining weight loss even if medication is eventually discontinued.

Mounjaro Crofton and Lifestyle Modification

NICE guidelines emphasise that pharmacological obesity treatment should always accompany comprehensive lifestyle interventions [4]. For Mounjaro Crofton patients, this means establishing a reduced-calorie diet (typically 500-750 kcal daily deficit), increasing physical activity to 150-300 minutes of moderate intensity exercise weekly, and addressing behavioural factors that contribute to weight gain. Our service provides access to dietary guidance and weight management resources to support these non-pharmacological components. The combination of tirzepatide's appetite suppression with deliberate lifestyle changes produces superior outcomes compared to medication alone.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 6 October 2026]
2. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. [accessed 6 October 2026]
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 6 October 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. [accessed 6 October 2026]
5. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 6 October 2026]
6. Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38-48. [accessed 6 October 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 6 October 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 6 October 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 6 October 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.